Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102, Bevacizumab, and Tislelizumab for Advanced Colorectal Cancer with Liver Metastases
NCT05314101Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in colorectal cancer (CRC), sponsored by Fujian Medical University Cancer Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05314101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05314101.